Want to see HK:2500 full AI Analyst Report?
2500 Stock Chart & Stats
HK$2.46
HK$0.00(0.00%)
At close: 4:00 PM EDT
HK$2.46
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.06 - HK$5.47
Previous CloseN/A
Volume6.42M
Average Volume (3M)2.48M
Market Cap
HK$762.95M
Enterprise ValueHK$562.20M
Total Cash (Recent Filing)HK$280.52M
Total Debt (Recent Filing)HK$216.43M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding441,010,220
10 Day Avg. Volume2,133,843
30 Day Avg. Volume2,483,027
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.53
Price to Sales (P/S)3.05
P/FCF Ratio-2.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.25
Revenue Forecast (FY)HK$791.75M
Bulls Say, Bears Say
Bulls Say
Focused TAVI & Interventional PortfolioA tight product focus on transcatheter aortic valve implantation (TAVI) and related interventional devices gives the company a durable, specialized market position within structural heart care. This supports long sales cycles, deep clinical relationships, and recurring consumable demand that can sustain revenue once procedure adoption grows.
Relatively Strong Balance SheetImproving leverage and a low debt-to-equity ratio provide financial flexibility to support ongoing R&D, regulatory processes, and commercialization efforts. A healthier balance sheet reduces default risk and lengthens runway compared with highly leveraged peers, making the company better placed to manage near-term cash burn.
Solid Unit Economics (gross Margins)Persistently solid gross margins indicate favorable unit economics for devices and consumables, implying that revenue recovery could translate relatively quickly into improved operating results. Strong product-level margins are a structural advantage for profitability once fixed-cost absorption improves with higher procedure volumes.
Bears Say
Severe Cash Burn & Weak Cash GenerationConsistent negative operating and free cash flow, with a marked deterioration in 2025, drives dependence on external financing and risks dilution or constrained investment. Weak cash generation limits ability to fund sales expansion, regulatory work, and R&D without tapping capital markets or cutting growth initiatives.
Persistent Structural UnprofitabilityOngoing operating and net losses with negative returns on equity indicate the company lacks current operating leverage to cover fixed costs. Structural unprofitability erodes shareholder value over time, pressures margins, and elevates the urgency for a sustainable path to breakeven or profitable segment scale.
Material Recent Revenue DeclineA roughly 30% revenue decline in 2025 undermines scaling benefits and delays fixed-cost absorption needed for profitability. Persistent top-line contraction magnifies cash burn and complicates commercialization plans, making execution risk and competitive pressures the main constraints on recovery over the next several quarters.
Venus Medtech (Hangzhou), Inc. Class H News
2500 FAQ
What was Venus Medtech (Hangzhou), Inc. Class H’s price range in the past 12 months?
Venus Medtech (Hangzhou), Inc. Class H lowest stock price was HK$1.06 and its highest was HK$5.47 in the past 12 months.
What is Venus Medtech (Hangzhou), Inc. Class H’s market cap?
Venus Medtech (Hangzhou), Inc. Class H’s market cap is HK$762.95M.
When is Venus Medtech (Hangzhou), Inc. Class H’s upcoming earnings report date?
Venus Medtech (Hangzhou), Inc. Class H’s upcoming earnings report date is Aug 27, 2026 which is in 53 days.
How were Venus Medtech (Hangzhou), Inc. Class H’s earnings last quarter?
Venus Medtech (Hangzhou), Inc. Class H released its earnings results on Mar 31, 2026. The company reported -HK$0.682 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.682.
Is Venus Medtech (Hangzhou), Inc. Class H overvalued?
According to Wall Street analysts Venus Medtech (Hangzhou), Inc. Class H’s price is currently Overvalued.
Does Venus Medtech (Hangzhou), Inc. Class H pay dividends?
Venus Medtech (Hangzhou), Inc. Class H does not currently pay dividends.
What is Venus Medtech (Hangzhou), Inc. Class H’s EPS estimate?
Venus Medtech (Hangzhou), Inc. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Venus Medtech (Hangzhou), Inc. Class H have?
Venus Medtech (Hangzhou), Inc. Class H has 441,010,220 shares outstanding.
What happened to Venus Medtech (Hangzhou), Inc. Class H’s price movement after its last earnings report?
Venus Medtech (Hangzhou), Inc. Class H reported an EPS of -HK$0.682 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.543%.
Which hedge fund is a major shareholder of Venus Medtech (Hangzhou), Inc. Class H?
Currently, no hedge funds are holding shares in HK:2500
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Venus Medtech (Hangzhou), Inc. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.31%
12-Months-Change
Fundamentals
Return on Equity
-21.29%
Trailing 12-Months
Asset Growth
-18.86%
Trailing 12-Months
Company Description
Venus Medtech (Hangzhou), Inc. Class H
Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Venus-Vitae, a balloon-expandable dry-tissue product; Venus-PowerX, a self-expanding dry-tissue product; Cardiovalve, a transcatheter valve replacement system for the treatment of patients with mitral regurgitation and in pivotal clinical trial for the treatment of patients with tricuspid regurgitation; Liwen RF, a radiofrequency ablation system for the treatment of hypertrophic cardiomyopathy; and renal artery denervation ablation system for the treatment of hypertension. In addition, the company offers procedural accessories comprising catheter sheath product and balloon catheter. Venus Medtech (Hangzhou) Inc. was incorporated in 2009 and is headquartered in Hangzhou, the People’s Republic of China.
Technical Analysis
MicroPort Scientific
―
MicroPort CardioFlow Medtech Corp.
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
―
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
―
Options Prices
Currently, No data available
---